Lack of Association Between ß-herpesvirus Infection and Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients in the Era of Antiviral Prophylaxis

Transplantation

Volumn 87, Issue 5, 2009, Pages 719-725

  Manuel, Oriol ^a   Kumar, Deepali ^a   Moussa, George ^b   Chen, Maggie H ^b   Pilewski, Joseph ^c   McCurry, Kenneth R ^c   Studer, Sean M ^c   Crespo, Maria ^c   Husain, Shahid ^d   Humar, Atul ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bronchiolitis obliterans; Chronic rejection; Cytomegalovirus; Human herpesvirus 6; Human herpesvirus 7; Lung transplantation

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIFUNGAL AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; COHORT ANALYSIS; CYTOMEGALOVIRUS; FEMALE; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; LOW DRUG DOSE; LUNG LAVAGE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECIPIENT; RISK ASSESSMENT; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; CYTOMEGALOVIRUS INFECTION; DRUG COMBINATION; GRAFT REJECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; POLYMERASE CHAIN REACTION; SYNDROME;

ADULT; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; GRAFT REJECTION; HERPESVIRUS 6, HUMAN; HERPESVIRUS 7, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PYRIMIDINES; SYNDROME; TRIAZOLES;

EID: 65649138051     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181963262     Document Type: Article

References (36)

1. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999; 340: 1081.
2. Trulock EP, Edwards LB, Taylor DO, et al. The registry of the international society for heart and lung transplantation: twentieth official adult lung and heart-lung transplant report-2003. J Heart Lung Transplant 2003; 22: 625.
3. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996; 15: 1.
4. Billings JL, Hertz MI, Savik K, et al. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21: 559.
5. Everard ML, Swarbrick A, Wrightham M, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 1994; 71: 428.
6. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5: 2031.
7. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146: 1419.
8. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation Washington University Lung Transplant Group. Am Rev Respir Dis 1993; 147:1017.
9. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15: 1200.
10. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17: 1255.
11. Keller CA, Cagle PT, Brown RW, et al. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest 1995; 107: 973.
12. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 1998; 116: 812.
13. Deborska-Materkowska D, Lewandowski Z, Sadowska A, et al. Fever, human herpesvirus-6 (HHV-6) seroconversion, and acute rejection episodes as a function of the initial seroprevalence for HHV-6 in renal transplant recipients. Transplant Proc 2006; 38: 139.
14. Kidd IM, Clark DA, Sabin CA, et al. Prospective study of human beta-herpesviruses after renal transplantation: association of human herpes-virus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000; 69: 2400.
15. Lautenschlager I, Linnavuori K, Lappalainen M, et al. HHV-6 reactivation is often associated with CMV infection in liver transplant patients. Transpl Int 2000; 13(suppl 1): S351.
16. Rogers J, Rohal S, Carrigan DR, et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000; 69: 2566.
17. Wade AW, McDonald AT, Acott PD, et al. Human herpesvirus-6 or Epstein-Barr virus infection and acute allograft rejection in pediatric kidney transplant recipients: greater risk for immunologically naive recipients. Transplant Proc 1998; 30: 2091.
18. Jacobs F, Knoop C, Brancart F, et al. Human herpesvirus-6 infection after lung and heart-lung transplantation: a prospective longitudinal study. Transplantation 2003; 75: 1996.
19. Michaelides A, Glare EM, Spelman DW, et al. beta-Herpesvirus (human cytomegalovirus and human herpesvirus 6) reactivation in at-risk lung transplant recipients and in human immunodeficiency virus-infected patients. J Infect Dis 2002; 186: 173.
20. Neurohr C, Huppmann P, Leuchte H, et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005; 5: 2982.
21. Ross DJ, Chan RC, Kubak B, et al. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpesvirus-7 infection after lung transplantation. Transplant Proc 2001; 33:2603.
22. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297.
23. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
24. McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pre-treatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005; 130: 528.
25. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008.
26. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 4.
27. Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170: 1120.
28. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46: 831.
29. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357.
30. Chaparro C, Chamberlain D, Maurer J, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients. Chest 1996; 110: 1150.
31. Razonable RR, Brown RA, Humar A, et al. PV16000 Study Group. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192: 1331.
32. Sharples LD, McNeil K, Stewart S, et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21: 271.
33. Ward KN, Gray JJ, Fotheringham MW, et al. IgG antibodies to human herpesvirus-6 in young children: changes in avidity of antibody correlate with time after infection. J Med Virol 1993; 39: 131.
34. Clark DA, Freeland ML, Mackie LK, et al. Prevalence of antibody to human herpesvirus 7 by age. J Infect Dis 1993; 168: 251.
35. Westall GP, Michaelides A, Williams TJ, et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190: 1076.
36. Chemaly RF, Yen-Lieberman B, Chapman J, et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant 2005; 5: 544.